CLRB — Cellectar Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1279704 ·
Last close
$2.57
Market Cap
$20.54M
52W High
$4.70
52W Low
$2.20
ADV30
100,087
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,793,942 | -5,653,946 | 11,119,761 | 8,347,090 | 7,784,674 |
| Dec 2025 | 0 | — | -5,690,629 | -5,295,221 | 14,978,321 | 13,196,033 | 6,441,157 |
| Sep 2025 | 0 | — | -4,850,696 | -4,443,877 | 14,627,590 | 12,554,289 | 6,630,284 |
| Jun 2025 | 0 | — | -6,037,529 | -5,447,911 | 13,695,183 | 11,041,027 | 7,610,171 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,580,348
Investing CF
$-9,258
Financing CF
$13,031,523
CapEx
$-64,664
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.43
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-274,787,446
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-22,372,796
Pretax Income TTM
$-20,840,955
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -22,979,844 | -21,791,037 | 14,978,321 | 6,441,157 | — | -23,118,217 |
| Dec 2024 | 0 | -51,777,698 | -44,581,446 | 25,474,047 | 11,179,366 | — | -47,583,001 |
| Dec 2023 | 0 | -38,960,643 | -42,770,610 | 12,075,580 | 27,234,548 | — | -32,376,974 |
| Dec 2022 | 0 | -28,813,773 | -31,792,618 | 21,589,790 | 13,436,546 | — | -25,222,301 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.79
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATOS | ATOSSA THERAPEUTICS, INC. | $20.65M | $2.07 | — |
| NEUP | Neuphoria Therapeutics Inc. | $20.97M | $3.88 | — |
| SKYE | Skye Bioscience, Inc. | $20.00M | $0.57 | — |
| LGVN | Longeveron Inc. | $21.16M | $0.70 | — |
| TVRD | Tvardi Therapeutics, Inc. | $19.70M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
2026-07-30 12:05 · Yahoo
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
2026-07-15 11:30 · Yahoo
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk
2026-07-11 11:10 · Yahoo
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Ann
2026-06-01 12:05 · Yahoo
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
2026-05-14 23:02 · Yahoo
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary
2026-05-14 21:08 · Yahoo
Cellectar (CLRB) Q1 2026 Earnings Transcript
2026-05-14 18:49 · Yahoo
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-14 11:15 · Yahoo
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
2026-05-11 12:05 · Yahoo
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
2026-05-07 16:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.